Follistim Aq
Biological Womens Health
NDC 0052-0326-01
General payments
$70,865
Research payments
$296,765
Through program year 2021, $70,865 in general payments and $296,765 in research payments were reported against Follistim Aq (Womens Health).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2021 | General | $7,497 | 376 |
| 2021 | Research | $45,795 | 1 |
| 2020 | General | $12,326 | 682 |
| 2020 | Research | $250,970 | 2 |
| 2019 | General | $51,043 | 1,539 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2021.
The top 5 of 18 specialties; each share is of general payments naming this product to practitioners with a specialty in 2021. Each practitioner is counted under their primary specialty.
The top 5 of 30 states; each share is of general payments naming this product in 2021 where a state was reported.
Records
2,597 general · 3 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.